相似文献
1
and Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma.
Cancer Discov. 2017 Aug;7(8):802-804. doi: 10.1158/2159-8290.CD-17-0610.
2
Modeling Renal Cell Carcinoma in Mice: and Inactivation Drive Tumor Grade.
Cancer Discov. 2017 Aug;7(8):900-917. doi: 10.1158/2159-8290.CD-17-0292. Epub 2017 May 4.
3
PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Cancer J. 2013 Jul-Aug;19(4):324-32. doi: 10.1097/PPO.0b013e3182a102d1.
4
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Cancer Genet. 2015 May;208(5):206-14. doi: 10.1016/j.cancergen.2015.02.008. Epub 2015 Feb 20.
5
Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16538-43. doi: 10.1073/pnas.1414789111. Epub 2014 Oct 30.
6
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Genes Chromosomes Cancer. 2014 Jan;53(1):38-51. doi: 10.1002/gcc.22116. Epub 2013 Oct 29.
7
Molecular genetics of clear-cell renal cell carcinoma.
J Clin Oncol. 2014 Jun 20;32(18):1968-76. doi: 10.1200/JCO.2012.45.2003. Epub 2014 May 12.
8
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Eur Urol. 2017 Mar;71(3):405-414. doi: 10.1016/j.eururo.2016.10.007. Epub 2016 Oct 15.
9
Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
F1000Res. 2024 Jun 14;12:918. doi: 10.12688/f1000research.136087.2. eCollection 2023.
10
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Neoplasia. 2019 Feb;21(2):247-256. doi: 10.1016/j.neo.2018.12.006. Epub 2019 Jan 16.
引用本文的文献
1
PBRM1 deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells.
J Cell Mol Med. 2022 Jul;26(14):3837-3849. doi: 10.1111/jcmm.17418. Epub 2022 Jun 7.
2
Effects of HMGA2 on the epithelial-mesenchymal transition-related genes in ACHN renal cell carcinoma cells-derived xenografts in nude mice.
BMC Cancer. 2022 Apr 19;22(1):421. doi: 10.1186/s12885-022-09537-w.
3
Risk Scores Based on Six Survival-Related RNAs in a Competing Endogenous Network Composed of Differentially Expressed RNAs Between Clear Cell Renal Cell Carcinoma Patients Carrying Wild-Type or Mutant Von Hippel-Lindau Serve Well to Predict Malignancy and Prognosis.
Front Oncol. 2021 Oct 25;11:726671. doi: 10.3389/fonc.2021.726671. eCollection 2021.
4
Identification of prognostic chromatin-remodeling genes in clear cell renal cell carcinoma.
Aging (Albany NY). 2020 Nov 20;12(24):25614-25642. doi: 10.18632/aging.104170.
本文引用的文献
1
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.
Nat Commun. 2017 Jun 8;8:15770. doi: 10.1038/ncomms15770.
2
Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.
Nat Med. 2017 Jul;23(7):869-877. doi: 10.1038/nm.4343. Epub 2017 May 29.
3
Modeling Renal Cell Carcinoma in Mice: and Inactivation Drive Tumor Grade.
Cancer Discov. 2017 Aug;7(8):900-917. doi: 10.1158/2159-8290.CD-17-0292. Epub 2017 May 4.
4
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Cell Rep. 2017 Mar 21;18(12):2893-2906. doi: 10.1016/j.celrep.2017.02.074.
5
Renal cell carcinoma.
Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9.
6
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Eur Urol. 2017 Mar;71(3):405-414. doi: 10.1016/j.eururo.2016.10.007. Epub 2016 Oct 15.
7
The somatic genomic landscape of chromophobe renal cell carcinoma.
Cancer Cell. 2014 Sep 8;26(3):319-330. doi: 10.1016/j.ccr.2014.07.014. Epub 2014 Aug 21.
8
BAP1 loss defines a new class of renal cell carcinoma.
Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323.
9
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
10
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.
Zotero 插件